Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00558766 · ClinicalTrials.gov registry record
Motor Cortex Reward Signaling in Parkinson Disease
A clinical trial, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 35
- Enrollment target
NCT00558766: Completed study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT00558766 is a clinical trial that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00558766 has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
Background: The brain releases signals to mark rewards for certain behavior. Some medications for Parkinson disease (PD) can cause some patients to engage in compulsive behavior, possibly because the medications affect this reward system. By using transcranial magnetic stimulation (TMS), researchers can study brain activity when an individual receives a reward. Objectives: To learn how the brains of people with PD behave when rewarded. To learn whether two common Parkinson medications (levodopa and pramipexole) change this behavior. To compare reward signals in the brains of healthy volunteers with reward signals in the brains of people with PD. Eligibility: Women between 50 and 80 years of age and men between 45 and 80 years of age. Participants will be divided into healthy volunteers and volunteers who have mild to moderate PD. Design: Prescreening will consist of a neurological examination and a series of questions about gambling habits and drug and alcohol use. Participation in a TMS study involving a computer game simulation of a slot machine: * Before the simulation, participants will receive TMS to establish a baseline response rate. * During the simulation, participants will play a game in which they will receive real money. TMS will be administered to each patient under three different conditions: * TMS administered when patients have not taken any Parkinson medication. * TMS administered after patients have taken levodopa. * TMS administered after patients have taken pramipexole....
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-11-08 |
| Est. Completion | 2011-06-13 |
What the finished NCT00558766 record still lists
NCT00558766 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00558766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00558766 about?
NCT00558766 is a clinical study titled "Motor Cortex Reward Signaling in Parkinson Disease". Background: The brain releases signals to mark rewards for certain behavior. Some medications for Parkinson disease (PD) can cause some patients to engage in compulsive behavior, possibly because the medications affect this reward system. By using transcranial magnetic stimulation (TMS), researche...
What is the current status of trial NCT00558766?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2007-11-08. Estimated completion is 2011-06-13.
Who is sponsoring clinical trial NCT00558766?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI